Phosphate metabolism in health and disease

M Peacock - Calcified tissue international, 2021 - Springer
Phosphorus, a 5A element with atomic weight of 31, comprises just over 0.6% of the
composition by weight of plants and animals. Three isotopes are available for studying …

Mechanisms of phosphate transport

M Levi, E Gratton, IC Forster, N Hernando… - Nature Reviews …, 2019 - nature.com
Over the past 25 years, successive cloning of SLC34A1, SLC34A2 and SLC34A3, which
encode the sodium-dependent inorganic phosphate (Pi) cotransport proteins 2a–2c, has …

The regulation of FGF23 under physiological and pathophysiological conditions

S Rausch, M Föller - Pflügers Archiv-European Journal of Physiology, 2022 - Springer
Abstract Fibroblast growth factor 23 (FGF23) is an important bone hormone that regulates
phosphate homeostasis in the kidney along with active vitamin D (1, 25 (OH) 2D3) and …

Emerging cross-talks between chronic kidney disease–mineral and bone disorder (CKD–MBD) and malnutrition–inflammation complex syndrome (MICS) in patients …

S Yamada, K Tsuruya, T Kitazono, T Nakano - Clinical and Experimental …, 2022 - Springer
Chronic kidney disease–mineral and bone disorder (CKD–MBD) is a systemic disorder that
affects multiple organs and systems and increases the risk of morbidity and mortality in …

Regulation of fibroblast growth factor 23 (FGF 23) in health and disease

L Bär, C Stournaras, F Lang, M Föller - FEBS letters, 2019 - Wiley Online Library
Fibroblast growth factor 23 (FGF 23) is mainly produced in the bone and, upon secretion,
forms a complex with a FGF receptor and coreceptor αKlotho. FGF 23 can exert several …

[HTML][HTML] Phosphate homeostasis, inflammation and the regulation of FGF-23

F Lang, C Leibrock, AA Pandyra… - Kidney and Blood …, 2018 - karger.com
Abstract Fibroblast growth factor 23 (FGF23) is released primarily from
osteoblasts/osteocytes in bone. In cooperation with the transmembrane protein Klotho …

Metformin: a candidate drug for renal diseases

R Corremans, BA Vervaet, PC D'Haese… - International journal of …, 2018 - mdpi.com
Over the past decades metformin has been the optimal first-line treatment for type 2 diabetes
mellitus (T2DM). Only in the last few years, it has become increasingly clear that metformin …

[HTML][HTML] Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on …

S Zeng, D Delic, C Chu, Y Xiong, T Luo, X Chen… - Biomedicine & …, 2022 - Elsevier
To date, the lowest protective SGLT2 inhibitor dose is unknown. We initially performed a
dose-response pilot study in normal rats. Based on the results of this pilot study we …

Vitamin D receptor mediates a myriad of biological actions dependent on its 1, 25‐dihydroxyvitamin D ligand: distinct regulatory themes revealed by induction of …

MR Haussler, S Livingston, ZL Sabir, CA Haussler… - JBMR …, 2021 - Wiley Online Library
The hormonal vitamin D metabolite, 1, 25‐dihydroxyvitamin D [1, 25 (OH) 2D], produced in
kidney, acts in numerous end organs via the nuclear vitamin D receptor (VDR) to trigger …

Protection of melatonin treatment and combination with traditional antibiotics against septic myocardial injury

W Di, Z Jin, W Lei, Q Liu, W Yang, S Zhang… - Cellular & Molecular …, 2023 - Springer
Background Heart failure is a common complication of sepsis with a high mortality rate. It
has been reported that melatonin can attenuate septic injury due to various properties. On …